Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results